In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Ligand Pharma (LGND – Research Report), with a price target of $160.00. The company’s shares closed last Friday at $114.83.

According to TipRanks, Prasad is a 3-star analyst with an average return of 2.6% and a 43.54% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical, Amneal Pharmaceuticals, and Tarsus Pharmaceuticals.

Currently, the analyst consensus on Ligand Pharma is a Strong Buy with an average price target of $149.80, which is a 30.45% upside from current levels. In a report released on March 2, RBC Capital also reiterated a Buy rating on the stock with a $155.00 price target.

The company has a one-year high of $129.90 and a one-year low of $67.72. Currently, Ligand Pharma has an average volume of 107.5K.

Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LGND in relation to earlier this year. Earlier this month, Octavio Espinoza, the CFO of LGND sold 5,000.00 shares for a total of $575,100.00.